<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04788888</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10342</org_study_id>
    <nct_id>NCT04788888</nct_id>
  </id_info>
  <brief_title>Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation</brief_title>
  <acronym>VANTAGE</acronym>
  <official_title>VANTAGE Clinical Trial Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of TAVR using the NAVITOR valve in a Global Investigation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The VANTAGE clinical trial will evaluate the safety and effectiveness of the Navitor valve in&#xD;
      patients with severe, symptomatic aortic stenosis who are at intermediate or low risk of&#xD;
      surgical mortality. This trial will also evaluate the safety and effectiveness of the Navitor&#xD;
      valve in a valve-in-valve application.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2033</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary safety and effectiveness endpoint is a composite of all-cause mortality or disabling stroke</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Non-hierarchical composite of all-cause mortality, disabling stroke, life threatening bleeding, acute kidney injury (stage 3), or major vascular complications</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Non-hierarchical composite of all-cause mortality or stroke</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Procedural success defined as successful vascular access, delivery and deployment of the Navitor valve; retrieval with the delivery system and correct positioning of a single Navitor valve in the proper anatomical location and no procedural mortality</measure>
    <time_frame>Procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mortality (all-cause and cardiovascular-related)</measure>
    <time_frame>30 days and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stroke (All stroke, disabling, and non-disabling)</measure>
    <time_frame>30 days and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Transient ischemic attack (TIA)</measure>
    <time_frame>30 days and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Bleeding (life threatening, disabling, and major)</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Major vascular complications at 30 days</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Acute kidney injury (Stage 3 requiring dialysis, Stage 3, and Stage 2)</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Permanent pacemaker insertion</measure>
    <time_frame>30 days and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>30 days and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Coronary obstruction requiring intervention</measure>
    <time_frame>30 days and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in functional status from baseline to follow-up assessments (e.g., NYHA classification, six-minute walk test, quality of life measures)</measure>
    <time_frame>30 days and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rehospitalization (valve-related, procedure-related, or heart failure)</measure>
    <time_frame>30 days and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Paravalvular leak (none/trace, mild, moderate or severe)</measure>
    <time_frame>Discharge, 30 days, 12 months and annually (when collected) through 10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in echocardiographic parameters from baseline to follow-up (e.g., mean effective orifice area, mean transvalvular gradient)</measure>
    <time_frame>30 days, 12 months and annually (when collected) through 10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Aortic valve reintervention</measure>
    <time_frame>at 30 days, 12 months, and annually through 10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Prosthetic valve endocarditis</measure>
    <time_frame>12 months and annually through 10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Structural valve deterioration</measure>
    <time_frame>12 months and annually through 10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Successful coronary access as needed</measure>
    <time_frame>12 months and annually through 10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Symptomatic prosthetic valve thrombosis</measure>
    <time_frame>12 months and annually through 10 years</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Symptomatic Severe Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Navitor Transcatheter Aortic Valve, FlexNav Delivery System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Navitor valve implantation, FlexNav Delivery system (small and large) and and Navitor Loading System (small and large)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Navitor Transcatheter Aortic Valve and FlexNav Delivery System</intervention_name>
    <description>For traditional application, the Navitor valve is indicated for transcatheter delivery in patients with symptomatic severe native aortic stenosis who are intermediate or low surgical risk.&#xD;
For the valve-in-valve application, the Navitor valve is indicated for use in patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic valve.&#xD;
Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Navitor valve and FlexNav Delivery system</description>
    <arm_group_label>Navitor Transcatheter Aortic Valve, FlexNav Delivery System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  In the judgement of the site's heart team, subject is deemed to be at intermediate or&#xD;
             low risk for open surgical aortic valve replacement (i.e., heart team estimates risk&#xD;
             of surgical mortality &lt; 7% at 30 days, considering the Society of Thoracic Surgeons&#xD;
             (STS) risk score, overall clinical status, and other clinical co-morbidities&#xD;
             unmeasured by the risk calculator&#xD;
&#xD;
          -  New York Heart Association (NYHA) Functional Classification of II, III, or IV&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of an acute myocardial infarction [defined as: Q wave MI, or non-Q wave MI&#xD;
             with total CK elevation of CK-MB ≥ twice normal in the presence of MB elevation and/or&#xD;
             troponin level elevation (WHO definition)] within 30 days prior to index procedure&#xD;
&#xD;
          -  Untreated clinically significant coronary artery disease requiring revascularization&#xD;
&#xD;
          -  Any percutaneous coronary or peripheral interventional procedure performed within 30&#xD;
             days prior (except pacemaker or ICD implant) to index procedure or planned within 30&#xD;
             days following the index procedure.&#xD;
&#xD;
          -  Blood dyscrasias as defined: leukopenia (WBC&lt;3000 mm3), acute anemia (Hb &lt; 9 g/dL),&#xD;
             thrombocytopenia (platelet count &lt;50,000 cells/mm³); history of bleeding diathesis or&#xD;
             coagulopathy&#xD;
&#xD;
          -  Recent (within 6 months prior to index procedure date) cerebrovascular accident (CVA)&#xD;
             or a transient ischemic attack (TIA)&#xD;
&#xD;
          -  Renal insufficiency (creatinine &gt; 3.0 mg/dL or estimated GFR &lt;30 ml/min/1.73m2) and/or&#xD;
             end stage renal disease requiring chronic dialysis&#xD;
&#xD;
          -  Untreated atrial fibrillation (e.g., patients with atrial fibrillation not on&#xD;
             anticoagulants)&#xD;
&#xD;
          -  Symptomatic carotid or vertebral artery disease, significant carotid or vertebral&#xD;
             artery disease requiring intervention, or successful treatment of carotid or vertebral&#xD;
             stenosis within 30 days prior to index procedure&#xD;
&#xD;
          -  Severe pulmonary hypertension with pulmonary systolic pressure greater than two-thirds&#xD;
             of systemic pressure&#xD;
&#xD;
          -  Severe lung disease (FEV1 &lt; 50% predicted) or currently on home oxygen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Azeem Latib, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Reardon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Methodist Hospital Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadia Bouhdi</last_name>
    <phone>+32479941037</phone>
    <email>nadia.bouhdi@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kyle Brunner</last_name>
    <phone>651-756-3482</phone>
    <email>kyle.brunner@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Andrew's Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen Worthley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tony Walton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lars Sondergaard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>August 8, 2021</last_update_submitted>
  <last_update_submitted_qc>August 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

